Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 951 to 960 of 1535 total matches.

Drugs for Open-Angle Glaucoma

   
The Medical Letter on Drugs and Therapeutics • Apr 28, 2025  (Issue 1727)
. For further information call: 800-211-2769 The Medical Letter ® Vol. 67 (1727) April 28, 2025 66 Table 1 ...
Glaucoma is a progressive optic neuropathy associated with increased intraocular pressure (IOP; normal range 8-22 mm Hg), which is the only disease-related factor that can be modified. Topical drugs that lower IOP are the first line of treatment for open-angle glaucoma.
Med Lett Drugs Ther. 2025 Apr 28;67(1727):65-8   doi:10.58347/tml.2025.1727a |  Show IntroductionHide Introduction

Advice for Travelers

   
The Medical Letter on Drugs and Therapeutics • Oct 07, 2019  (Issue 1582)
The Medical Letter ® Vol. 61 (1582) October 7, 2019 They should not be used for empiric treatment of TD ...
Patients who receive pretravel advice can reduce their risk for many travel-related conditions. Vaccines recommended for travelers are reviewed in a separate issue.
Med Lett Drugs Ther. 2019 Oct 7;61(1582):153-60 |  Show IntroductionHide Introduction

Drugs for Migraine

   
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023  (Issue 1678)
® Vol. 65 (1678) June 12, 2023 90 Patients of stroke, transient ischemic attack, or hemiplegic ...
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine pain without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine in most patients without vascular disease. Treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):89-96   doi:10.58347/tml.2023.1678a |  Show IntroductionHide Introduction

Drugs for Asthma

   
The Medical Letter on Drugs and Therapeutics • Nov 25, 2024  (Issue 1716)
of this material is strictly prohibited. For further information call: 800-211-2769 The Medical Letter ® Vol. 66 ...
The goal of asthma treatment is to control symptoms, prevent exacerbations, and maintain normal lung function. Management of acute exacerbations in the emergency department is not discussed here.
Med Lett Drugs Ther. 2024 Nov 25;66(1716):185-92   doi:10.58347/tml.2024.1716a |  Show IntroductionHide Introduction

Interferon Beta-1b for Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Jul 09, 1993  (Issue 900)
. Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB SITE: http://www.medletter.com The Medical Letter, Vol ...
Interferon β-1b (Betaseron - Berlex), an analog of human interferon β pro-duced in E. coli, may soon be approved by the US Food and Drug Administration for treatment of relapsing-remitting multiple sclerosis (MS), the most common form of the disease (G Mitchell, Med Clin North Am, 77:231, 1993).
Med Lett Drugs Ther. 1993 Jul 9;35(900):61-2 |  Show IntroductionHide Introduction

Portable Prothrombin Time Monitoris

   
The Medical Letter on Drugs and Therapeutics • Mar 17, 1995  (Issue 944)
The Medical Letter, Vol. 37 (Issue 944) March 17, 1995, p. 24 Copyright  The Medical Letter UNAUTHORIZED ...
Two portable instruments for monitoring prothrombin time have been approved by the US Food and Drug Administration (FDA). The Coumatrak (DuPont Pharma) and CoaguChek (Boehringer Mannheim Diagnostics) are marketed in the USA only for use by healthcare professionals. In Europe, however, the CoaguChek is also marketed for use by patients. A CoaguChek Plus portable system, which measures activated partial thromboplastin time (APTT) as well as prothrombin time, is also available in both Europe and the USA.
Med Lett Drugs Ther. 1995 Mar 17;37(944):24 |  Show IntroductionHide Introduction

Bellafill for Acne Scars

   
The Medical Letter on Drugs and Therapeutics • Jun 22, 2015  (Issue 1471)
from unintentional injection of dermal fillers into facial blood vessels. 94 The Medical Letter ® Vol. 57 (1471 ...
Bellafill (Suneva), a dermal filler approved earlier for correction of nasolabial folds, has now also been approved by the FDA for correction of moderate to severe, atrophic, distensible facial acne scars on the cheek in adults ≥21 years old. It is the only dermal filler approved in the US for correction of facial acne scars.
Med Lett Drugs Ther. 2015 Jun 22;57(1471):93-4 |  Show IntroductionHide Introduction

COVID-19 Update: Pfizer Bivalent Vaccine Booster Dose for Children 6 Months to 4 Years Old

   
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023  (Issue 1674)
at: www.medicalletter.org/drugs-for-covid-19. The Medical Letter ® Vol. 65 (1674) April 17, 2023 vaccines Spikevax COVID-19 ...
The FDA has expanded its Emergency Use Authorization (EUA) for the COVID-19 vaccine manufactured by Pfizer/BioNTech (Comirnaty) to permit use of the bivalent formulation (containing mRNA from the original and BA.4/5 Omicron strains of SARS-CoV-2) as a booster dose in children 6 months to 4 years old who completed the primary series with 3 doses of the monovalent formulation ≥2 months previously. The Pfizer bivalent vaccine had previously been authorized for use as a booster dose in persons ≥5 years old and as a third primary dose in children 6 months to 4 years old. Booster...
Med Lett Drugs Ther. 2023 Apr 17;65(1674):63-4   doi:10.58347/tml.2023.1674c |  Show IntroductionHide Introduction

In Brief: Casgevy for Beta Thalassemia

   
The Medical Letter on Drugs and Therapeutics • May 13, 2024  (Issue 1702)
dose is $2.2 million for Casgevy compared to $2.8 million for Zynteglo.5 The Medical Letter ® Vol ...
Exagamglogene autotemcel (Casgevy – Vertex), a cell-based gene therapy recently approved for treatment of sickle cell disease1, has now been approved by the FDA for treatment of patients ≥12 years old with transfusion-dependent beta thalassemia. Casgevy is the first gene therapy that uses CRISPR/Cas9 gene-editing technology to be approved in the US for any disorder. Betibeglogene autotemcel (Zynteglo), an autologous lentiviral vector cell-based gene therapy, was approved in the US in 2022 for treatment of transfusion-dependent beta thalassemia.
Med Lett Drugs Ther. 2024 May 13;66(1702):79   doi:10.58347/tml.2024.1702d |  Show IntroductionHide Introduction

Sunscreens

   
The Medical Letter on Drugs and Therapeutics • Jun 23, 2025  (Issue 1731)
-2769 The Medical Letter ® Vol. 67 (1731) June 23, 2025 98 Table 1. Some FDA-Approved Sunscreen ...
Excessive exposure to ultraviolet (UV) radiation can cause erythema, photoaging, and skin cancer. Sunscreens are widely used to reduce these risks, but questions remain about their effectiveness and safety. In 2021, the FDA proposed a rule that would require additional safety studies for some sunscreen active ingredients and mandate better UVA protection in sunscreen products.
Med Lett Drugs Ther. 2025 Jun 23;67(1731):97-102   doi:10.58347/tml.2025.1731a |  Show IntroductionHide Introduction